Distinguished in Osteosarcoma

Michaela M. Nathrath

Hannover, NI, DE 
Distinguished in Osteosarcoma
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Michaela Nathrath practices in Hannover, Germany. Ms. Nathrath is rated as a Distinguished expert by MediFind in the treatment of Osteosarcoma. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Turcot Syndrome.

Her clinical research consists of co-authoring 78 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 39 articles in the study of Osteosarcoma.

Gender
Female

Locations

Hannover, NI, Germany
Other Locations
Munich, BY, Germany
Kassel, HE, Germany
Stuttgart, BW, Germany
Neuherberg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisolone, Vincristine
Study Phase: Phase 3

78 Total Publications

Investigation of DNA damage response genes validates the role of DNA repair in pediatric cancer risk and identifies SMARCAL1 as novel osteosarcoma predisposition gene.
Investigation of DNA damage response genes validates the role of DNA repair in pediatric cancer risk and identifies SMARCAL1 as novel osteosarcoma predisposition gene.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nathrath's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile